Stock Track | Ascendis Pharma Soars 5.87% After Beating Q4 Estimates on Strong Sales Growth

Stock Track

Feb 13, 2025

Shares of Ascendis Pharma A/S surged 5.87% in Wednesday's session, outperforming the broader market. The biopharmaceutical company's stock rallied after reporting better-than-expected fourth-quarter earnings and revenue, fueled by strong sales growth.

Ascendis Pharma's fourth-quarter GAAP earnings per share of €(0.64) beat the consensus estimate of €(1.07). Meanwhile, its revenue of €173.916 million surpassed expectations of €111.178 million, driven by robust demand for its products.

The company's impressive financial results and positive outlook for continued growth have boosted investor confidence, leading to the significant stock price increase. Analysts expect Ascendis Pharma's innovative pipeline and expanding commercial portfolio to drive further revenue and earnings growth in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1117203444"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117203444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117203444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117203444","market":"us","top_or_hot":-1,"title":"Stock Track | Ascendis Pharma Soars 5.87% After Beating Q4 Estimates on Strong Sales Growth","media":"Stock Track","content":"<p>Shares of Ascendis Pharma A/S surged 5.87% in Wednesday's session, outperforming the broader market. The biopharmaceutical company's stock rallied after reporting better-than-expected fourth-quarter earnings and revenue, fueled by strong sales growth.</p>\n\n<p>Ascendis Pharma's fourth-quarter GAAP earnings per share of €(0.64) beat the consensus estimate of €(1.07). Meanwhile, its revenue of €173.916 million surpassed expectations of €111.178 million, driven by robust demand for its products.</p>\n\n<p>The company's impressive financial results and positive outlook for continued growth have boosted investor confidence, leading to the significant stock price increase. Analysts expect Ascendis Pharma's innovative pipeline and expanding commercial portfolio to drive further revenue and earnings growth in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ascendis Pharma Soars 5.87% After Beating Q4 Estimates on Strong Sales Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ascendis Pharma Soars 5.87% After Beating Q4 Estimates on Strong Sales Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Ascendis Pharma A/S surged 5.87% in Wednesday's session, outperforming the broader market. The biopharmaceutical company's stock rallied after reporting better-than-expected fourth-quarter earnings and revenue, fueled by strong sales growth.</p>\n\n<p>Ascendis Pharma's fourth-quarter GAAP earnings per share of €(0.64) beat the consensus estimate of €(1.07). Meanwhile, its revenue of €173.916 million surpassed expectations of €111.178 million, driven by robust demand for its products.</p>\n\n<p>The company's impressive financial results and positive outlook for continued growth have boosted investor confidence, leading to the significant stock price increase. Analysts expect Ascendis Pharma's innovative pipeline and expanding commercial portfolio to drive further revenue and earnings growth in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASND","symbol_name":"Ascendis Pharma A/S","start_time":0,"source_url":"","article_id":"1117203444","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117203444","pubTimestamp":1739394514,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ascendis Pharma A/S surged 5.87% in Wednesday's session, outperforming the broader market. The biopharmaceutical company's stock rallied after reporting better-than-expected fourth-quarter earnings and revenue, fueled by strong sales growth.Ascendis Pharma's fourth-quarter GAAP earnings per share of  beat the consensus estimate of . Meanwhile, its revenue of 173.916 million surpassed expectations of 111.178 million, driven by robust demand for its products.The company's impressive fina","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ASND":"Ascendis Pharma A/S"},"translate_title":"Ascendis Pharma第四季度销售增长强劲，超出预期，股价飙升5.87%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":1},"content_text":"Shares of Ascendis Pharma A/S surged 5.87% in Wednesday's session, outperforming the broader market. The biopharmaceutical company's stock rallied after reporting better-than-expected fourth-quarter earnings and revenue, fueled by strong sales growth.\nAscendis Pharma's fourth-quarter GAAP earnings per share of €(0.64) beat the consensus estimate of €(1.07). Meanwhile, its revenue of €173.916 million surpassed expectations of €111.178 million, driven by robust demand for its products.\nThe company's impressive financial results and positive outlook for continued growth have boosted investor confidence, leading to the significant stock price increase. Analysts expect Ascendis Pharma's innovative pipeline and expanding commercial portfolio to drive further revenue and earnings growth in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}